Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2010

Open Access 01-12-2010 | Research

Valuation of scleroderma and psoriatic arthritis health states by the general public

Authors: Dinesh Khanna, Tracy Frech, Puja P Khanna, Robert M Kaplan, Mark H Eckman, Ron D Hays, Shaari S Ginsburg, Anthony C Leonard, Joel Tsevat

Published in: Health and Quality of Life Outcomes | Issue 1/2010

Login to get access

Abstract

Objective

Psoriatic arthritis (PsA) and scleroderma (SSc) are chronic rheumatic disorders with detrimental effects on health-related quality of life. Our objective was to assess health values (utilities) from the general public for health states common to people with PsA and SSc for economic evaluations.

Methods

Adult subjects from the general population in a Midwestern city (N = 218) completed the SF-12 Health Survey and computer-assisted 0-100 rating scale (RS), time trade-off (TTO, range: 0.0-1.0) and standard gamble (SG, range: 0.0-1.0) utility assessments for several hypothetical PsA and SSc health states.

Results

Subjects included 135 (62%) females, 143 (66%) Caucasians, and 62 (28%) African-Americans. The mean (SD) scores for the SF-12 Physical Component Summary scale were 52.9 (8.3) and for the SF-12 Mental Component Summary scale were 49.0 (9.1), close to population norms. The mean RS, TTO, and SG scores for PsA health states varied with severity, ranging from 20.2 to 63.7 (14.4-20.3) for the RS 0.29 to 0.78 (0.24-0.31) for the TTO, and 0.48 to 0.82 (0.24-0.34) for the SG. The mean RS, TTO, and SG scores for SSc health states were 25.3-69.7 (15.2-16.3) for the RS, 0.36-0.80 (0.25-0.31) for the TTO, and 0.50-0.81 (0.26-0.32) for the SG, depending on disease severity.

Conclusion

Health utilities for PsA and SSc health states as assessed from the general public reflect the severity of the diseases. These descriptive findings could have implications regarding comparative effectiveness research for tests and treatments for PsA and SSc.

Literature
  1. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M: Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009,23(6):683–691. 10.1111/j.1468-3083.2009.03159.xPubMedView Article
  2. Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, Tsevat J: Health values of patients with systemic sclerosis. Arthritis Rheum 2007,57(1):86–93. 10.1002/art.22465PubMedView Article
  3. Helliwell PS, Taylor WJ: Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005,64(Suppl 2):ii3–8. 10.1136/ard.2004.032318PubMed CentralPubMed
  4. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003,48(8):2246–2255. 10.1002/art.11073PubMedView Article
  5. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ: Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994,33(9):834–839. 10.1093/rheumatology/33.9.834PubMedView Article
  6. Clements PJ: Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000,14(1):1–16. 10.1053/berh.1999.0074PubMedView Article
  7. Charles C, Clements P, Furst DE: Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006,367(9523):1683–1691. 10.1016/S0140-6736(06)68737-0PubMedView Article
  8. Khanna D, Furst DE, Wong WK, Tsevat J, Clements PJ, Park GS, Postlethwaite AE, Ahmed M, Ginsburg S, Hays RD: Reliability, validity, and minimally important differences of the SF-6 D in systemic sclerosis. Qual Life Res 2007,16(6):1083–1092. 10.1007/s11136-007-9207-3PubMedView Article
  9. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001,137(3):280–284.PubMed
  10. Ware JWJKM, Keller S: SF-36 Physical and Mental Summary Scales: A User's Manual. Boston, Mass: Health Institue, New England Medical Center; 1994.
  11. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, et al.: Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005,32(5):832–840.PubMed
  12. Husted JH, Husted G: Ethics and managed care. Mastering the administration of the unforeseen. Interview by Jim O'Malley. Aspens Advis Nurse Exec 1997,12(6):1. 3–5PubMed
  13. Tsevat J, Weeks JC, Guadagnoli E, Tosteson AN, Mangione CM, Pliskin JS, Weinstein MC, Cleary PD: Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy. J Gen Intern Med 1994,9(10):576–582. 10.1007/BF02599287PubMedView Article
  14. Zug KA, Littenberg B, Baughman RD, Kneeland T, Nease RF, Sumner W, O'Connor GT, Jones R, Morrison E, Cimis R: Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 1995,131(5):561–568. 10.1001/archderm.131.5.561PubMedView Article
  15. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996,276(15):1253–1258. 10.1001/jama.276.15.1253PubMedView Article
  16. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996,34(3):220–233. 10.1097/00005650-199603000-00003PubMedView Article
  17. Steen VD, Medsger TA Jr: The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997,40(11):1984–1991. 10.1002/art.1780401110PubMedView Article
  18. Husted J, Gladman DD, Farewell VT, Long JA: Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic Arthritis. J Rheumatol 1996,23(6):1015–1019.PubMed
  19. Sieber WJ: Quality of well being self-administered (QWB-SA) scale. 2004. --- Either ISSN or Journal title must be supplied.
  20. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG: Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006,26(4):391–400. 10.1177/0272989X06290497PubMedView Article
  21. Kaplan RM: The future of outcomes measurement in rheumatology. Am J Manag Care 2007,13(Suppl 9):S252–255.PubMed
  22. Kaplan RM, Patterson TL, Kerner DN, Atkinson JH, Heaton RK, Grant I: The Quality of Well-Being scale in asymptomatic HIV-infected patients. HNRC Group. HIV Neural Behavioral Research Center. Qual Life Res 1997,6(6):507–514. 10.1023/A:1018456031659PubMedView Article
  23. UMaker User's Manual UMDNJ Technical Report 1999. --- Either first page or author must be supplied.
  24. Arias E: United States life tables, 2000. Natl Vital Stat Rep 2002,51(3):1–38.PubMed
  25. Stalmeier PF, Goldstein MK, Holmes AM, Lenert L, Miyamoto J, Stiggelbout AM, Torrance GW, Tsevat J: What should be reported in a methods section on utility assessment? Med Decis Making 2001,21(3):200–207.PubMedView Article
  26. Stalmeier PF: Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments. Med Decis Making 2002,22(1):53–64.PubMedView Article
  27. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, et al.: Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005,52(2):592–600. 10.1002/art.20787PubMedView Article
  28. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990,17(6):809–812.PubMed
  29. Torrance GW: Measurement of health state utilities for economic appraisal. J Health Econ 1986,5(1):1–30. 10.1016/0167-6296(86)90020-2PubMedView Article
  30. Kind P, Dolan P, Gudex C, Williams A: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998,316(7133):736–741.PubMed CentralPubMedView Article
  31. Frosch DL, Kaplan RM, Ganiats TG, Groessl EJ, Sieber WJ, Weisman MH: Validity of self-administered quality of well-being scale in musculoskeletal disease. Arthritis Rheum 2004,51(1):28–33. 10.1002/art.20071PubMedView Article
  32. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992,30(6):473–483. 10.1097/00005650-199206000-00002PubMedView Article
  33. Yi MS, Luckhaupt S, Mrus JM, Tsevat J: Do medical house officers value the health of veterans differently from the health of non-veterans? Health Qual Life Outcomes 2004, 2: 19. 10.1186/1477-7525-2-19PubMed CentralPubMedView Article
  34. Khanna D, Kaplan RM, Eckman MH, Hays RD, Leonard AC, Ginsburg SS, Tsevat J: A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utilities. Med Decis Making 2009,29(1):7–14. 10.1177/0272989X08322010PubMed CentralPubMedView Article
  35. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P: Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004,50(3):953–960. 10.1002/art.20048PubMedView Article
  36. Brazier J, Roberts J, Tsuchiya A, Busschbach J: A comparison of the EQ-5 D and SF-6 D across seven patient groups. Health Econ 2004,13(9):873–884. 10.1002/hec.866PubMedView Article
  37. Grieve R, Grishchenko M, Cairns J: SF-6 D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ 2009,10(1):15–23. 10.1007/s10198-008-0097-2PubMedView Article
  38. Tsuchiya A, Brazier J, Roberts J: Comparison of valuation methods used to generate the EQ-5 D and the SF-6 D value sets. J Health Econ 2006,25(2):334–346. 10.1016/j.jhealeco.2005.09.003PubMedView Article
  39. Pyne JM, Fortney JC, Tripathi S, Feeny D, Ubel P, Brazier J: How bad is depression? Preference score estimates from depressed patients and the general population. Health Serv Res 2009,44(4):1406–1423. 10.1111/j.1475-6773.2009.00974.xPubMed CentralPubMedView Article
  40. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC: The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996,276(14):1172–1177. 10.1001/jama.276.14.1172PubMedView Article
  41. Stiggelbout AM, de Vogel-Voogt E: Health state utilities: a framework for studying the gap between the imagined and the real. Value Health 2008,11(1):76–87.PubMedView Article
  42. Torrance GW: Preferences for health outcomes and cost-utility analysis. Am J Manag Care 1997,3(Suppl):S8–20.PubMed
  43. Torrance GW: Utility approach to measuring health-related quality of life. J Chronic Dis 1987,40(6):593–603. 10.1016/0021-9681(87)90019-1PubMedView Article
  44. US Census Bureau. USA Quick facts [http://​quickfacts.​census.​gov/​qfd/​states/​00000.​html] --- Either ISSN or Journal title must be supplied.
  45. Hahn EA, Cella D, Dobrez DG, Weiss BD, Du H, Lai JS, Victorson D, Garcia SF: The impact of literacy on health-related quality of life measurement and outcomes in cancer outpatients. Qual Life Res 2007,16(3):495–507. 10.1007/s11136-006-9128-6PubMedView Article
  46. Suarez-Almazor ME, Conner-Spady B: Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses. J Rheumatol 2001,28(3):648–656.PubMed
  47. Grossman JM, Brahn E: Rheumatoid arthritis: current clinical and research directions. J Womens Health 1997,6(6):627–638. 10.1089/jwh.1997.6.627PubMedView Article
Metadata
Title
Valuation of scleroderma and psoriatic arthritis health states by the general public
Authors
Dinesh Khanna
Tracy Frech
Puja P Khanna
Robert M Kaplan
Mark H Eckman
Ron D Hays
Shaari S Ginsburg
Anthony C Leonard
Joel Tsevat
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2010
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-8-112

Other articles of this Issue 1/2010

Health and Quality of Life Outcomes 1/2010 Go to the issue

Research

Quality of life and life circumstances in German myasthenia gravis patients

Research

Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study

Research

The well-being and treatment satisfaction of diabetic patients in primary care

Research

Changes in the SF-8 scores among healthy non-smoking school teachers after the enforcement of a smoke-free school policy: a comparison by passive smoke status

Review

Quality of life measurement in women with cervical cancer: implications for Chinese cervical cancer survivors

Research

Association of measured physical performance and demographic and health characteristics with self-reported physical function: implications for the interpretation of self-reported limitations